Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga · 1d ago
Share
Listen to the news
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Perrigo Company PLC (NYSE:PRGO)
- Dividend Yield: 8.83%
- Canaccord Genuity analyst Susan Anderson maintained a Buy rating and cut the price target from $40 to $20 on Nov. 6, 2025. This analyst has an accuracy rate of 62%.
- JP Morgan analyst Chris Scott downgraded the stock from Overweight to Neutral and slashed the price target from $32 to $20 on Nov. 6, 2025. This analyst has an accuracy rate of 65%.
- Recent News: On Nov. 5, Perrigo reported mixed third-quarter financial results and cut its FY25 adjusted EPS guidance below estimates.
- Benzinga Pro’s real-time newsfeed alerted to latest PRGO news.
Bristol-Myers Squibb Co (NYSE:BMY)
- Dividend Yield: 4.81%
- Morgan Stanley analyst Terence Flynn maintained an Underweight rating and cut the price target from $37 to $36 on Dec. 12, 2025. This analyst has an accuracy rate of 69%.
- Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy with a price target of $62 on Dec. 12, 2025. This analyst has an accuracy rate of 81%
- Recent News: On Dec. 11, Bristol Myers Squibb received FDA Priority Review for Opdivo Plus AVD combination sBLA in untreated stage III/IV cHL.
- Benzinga Pro's real-time newsfeed alerted to latest BMY news
CVS Health Corp (NYSE:CVS)
- Dividend Yield: 3.35%
- Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $95 to $98 on Dec. 10, 2025. This analyst has an accuracy rate of 67%.
- UBS analyst Kevin Caliendo maintained a Buy rating and increased the price target from $96 to $97 on Dec. 10, 2025. This analyst has an accuracy rate of 65%
- Recent News: On Dec. 9, CVS raised its FY2025 adjusted EPS and sales guidance.
- Benzinga Pro’s real-time newsfeed alerted to latest CVS news
Read More:
Photo via Shutterstock
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2025 Webull. All Rights Reserved